After three years, there was a 30% reduction in emergency department visits, 25% reduction in hospitalizations, 40% reduction in overdose and 50% reduction in drug-related deaths
One framing point that matters from the start: JRNYS is not a clinic, and it is not the prescribing entity
Efficacy and tolerability of tirzepatide, a dual glucose-dependent insulinotropic peptide and glucagon-like peptide-1 receptor agonist in patients with type 2 diabetes: A 12-week, randomized, double-blind, placebo-controlled study to evaluate different dose-escalation regimens
Growing Demand The growing demand for GLP-1 medications continues to place pressure on insurance carriers, employers, and government programs attempting to balance patient access with rising pharmaceutical expenditures
doi: 10.1186/1471-2288-14-43 14 Garcia-FloresVRomeroRMillerDXuYDoneBVeerapaneniCet al